Keywords: Eylea, Regeneron, Bayer, USA, Retinal specialists, Wet AMD, Prescribing, Decision Resources
Recent Eylea growth in USA appears to be coming from expanded uptake among prescribers
Article | 07 January 2013
After one year on the market, 86% of US retinal specialists have prescribed Regeneron's (Nasdaq: REGN) Eylea (aflibercept, injection) to at ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
